October 7th, 2013
Selections from Richard Lehman’s Literature Review: October 7th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include several papers on the CV safety of diabetes drugs, a follow-up report from the WHI on hormone therapy, clopidogrel and smoking, and more.
May 17th, 2012
FDA Approves Generic Clopidogrel as Plavix Loses Patent Protection
Larry Husten, PHD
For the second time in the past 6 months, a cardiology mainstay drug has lost patent protection and gone generic. Today, the FDA announced that it had approved several generic versions of clopidogrel (Plavix), the antiplatelet drug that for many years was the second best-selling drug in the world. Last November, the best-selling drug of all time, […]
March 24th, 2012
Novel Antiplatelet Agent Reduces CV Events But Increases Bleeding
Larry Husten, PHD
Vorapaxar, the novel antiplatelet agent from Merck, appears to effectively reduce cardiovascular death and ischemic events in patients with MI, ischemic stroke, or peripheral vascular disease, but its potential utility is clouded by bleeding complications, including intracranial hemorrhage. Results from the TRA 2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial were presented […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?